* AxoGen Inc AXGN.OQ AXGN.O is expected to show a rise
in
quarterly revenue when it reports results on August 7.
* The Alachua Florida-based company is expected to report
a
13.4% increase in revenue to $39.08 million from $34.45 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for AxoGen Inc is for a
loss
of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AxoGen Inc
is
$17, above its last closing price of $8.58.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.15 -0.14 -0.10 Beat 31
Dec. 31 2023 -0.11 -0.11 -0.03 Beat 73.6
Sep. 30 2022 -0.13 -0.12 -0.01 Beat 91.8
Jun. 30 2022 -0.14 -0.14 -0.06 Beat 58.6
Mar. -0.16 -0.15 -0.20 Missed -30.4
31 2022
Dec. 31 2021 -0.12 -0.13 -0.08 Beat 39.1
Sep. 30 2021 -0.14 -0.14 -0.09 Beat 34.4
Jun. 30 2021 -0.13 -0.13 -0.09 Beat 29.9
This summary was machine generated August 4 at 21:12 GMT. All
figures in US dollars unless otherwise stated